Clinical Trial Update: Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder [Phase 1, Phase 2]

View source ↗

Summary

A proof-of-concept safety study of CPP-109 (vigabatrin) for treatment-refractory Tourette's Disorder has completed phases 1 and 2 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Disorder

Drugs mentioned

• CPP-109 (vigabatrin)

Snippet

Sponsor: Barbara J. Coffey | Conditions: Tourette's Disorder | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-01-19